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DEMENTIA
GONE VIRAL
How years of research linking Alzheimer’s
Disease and infections has been lost in
translation
By Mary Sawyer

The Diagnosis

T

he tangles in the brain begin
slowly, like vines in a jungle.
They feed, engorging themselves
as they expand and grow. They
bend back and forth, in and out,
becoming entangled like the roots
of a tree digging deeper and deeper into the ground. Soon the vines
become so entangled that they are
no longer individual vines clinging to one another, but rather a
single mass taking up the space
that used to exist. This space in
the brain once filled by cells called
neurons and glia has now fallen
victim to the grip of the tangles.
Typically masses of tangles are ob-

20

served in brains infected with Alzheimer’s Disease, but it turns out
they play a role in the pathological development of bacteria and
virus induced dementia. These
tangles, also called neurofibrillary tangles (NFT), are composed
of tau proteins in an abnormal
state. Normally, tau proteins stabilize neuronal structures within
the brain.1 Thus, abnormal tau
proteins deteriorate networks of
neurons, which are typically created from neurons communicating
with one another via synapses.2
These synapses are at the end of
neurons and enable neuronal com-

munication through the release of
chemicals, ultimately allowing
neurons to “talk” and create a network. Through the work of Dr.
Alzheimer, we found another key
player in the destruction of neuronal networks, aside from NFTs.
In 1907 Dr. Alzheimer discovered NFTs during an autopsy of
the brain of his patient who had
progressive cognitive decline.
Confused by his clinical observations and unable to determine the
cause, he investigated his patient’s
brain further. In addition to the
observed NFTs within the cells,
he found clumps of proteins in
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regions of the brain where he had
expected to find cells and brain tissue.3 These “clumps” were actually
amyloid-beta plaques (Aβ). Existing concurrently, NFTs and Aβ
plaques deprive brain cells of the
oxygen and cortical space they need
to survive, forcing the cells into a
neurodegenerative state (Figure 1).
This pathology of AD manifests in
a loss of memory and cognitive
function, leading to heavy burdens
of this disease across thousands
of families all over the world.4
Over 100 years later, a
speculative AD diagnosis is made
according to the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition and the
National Institute of Neurological
Disorders and Stroke-Alzheimer
Disease and Related Disorders
working group.6 AD is a specific type of dementia for which an
official confirmation of the disease still requires an autopsy of
the brain after death. Five million
Americans are living with AD, and
at the current disease rate there
could be as many as 16 million
people affected by the year 2050
.7 Described as one of the “holy
grails of science”, AD research has
gained momentum as scientists
search for a cure. Most recently
AD made headlines because of
Bill Gates’ donation of 50 million
dollars in funding.8 Despite advances in research and technology,
a cure for AD remains an enigma.
Imagine a 90 year-old man
wandering the streets of a neighborhood in which he has lived for
over 30 years. Every few feet he
stops and looks around him with
a confused look on his face. Every-

thing is unfamiliar, even though
he has lived in the same place for
several years. This man suffers
from sporadic AD, also known
as late onset AD (LOAD).6 His
brain has lost a significant amount
of neurons, leaving gaping holes
where Aβ plaques now form. Neural networks have been destroyed
by the intracellular NFTs. The
disease started slowly, creeping
in on his memories, settling in
to stay. While many experience
the cognitive decline that comes
with age, there is a difference between the aging process and the
disease this old man suffers from.
Most notably, the pathology of
his brain is unique to those with
AD in that he has significant neuronal loss, as well as NFTs and
Aβ plaques present. Elderly individuals having trouble recalling
memories or thoughts may have
changes to their neuronal networks, including loss of synapses.9 Although this aging person
has synaptic loss, they do not have
significant neuronal death and
therefore, do not have dementia.
Dementia is an umbrella
term for diseases classified as a disturbance to cognition and memory in such a way that interferes
with daily activities suitable for
the age of the person presenting
symptoms.4 Thus, AD is a type
of dementia defined by the presence of NFTs and Aβ plaques;
AD is further split into two types:
LOAD and Early-Onset Dementia (EOD).6 LOAD, also called
sporadic AD, develops in individuals with no family history of
the disease. Typically genetics are
discussed relative to EOD, or fa-

milial AD; however, genetics may
also play a role in LOAD. Scientists found that mutations of the
Apolipoprotein E (ApoE) gene are
associated with LOAD. In healthy
individuals this gene codes for a
protein that performs many functions. One of these functions is to
clear Aβ from the space between
cells, ultimately preventing plaque
accumulation.10 Thus, with a mutation to this gene, some individuals may be more susceptible to
build up of Aβ plaque. One study
looked at the brains of 39 individuals with a confirmed AD diagnosis and 35 healthy individuals;
62% of AD-infected participants
had an ApoE mutation, compared to only 20% of the healthy
participants.11 This indicates that
genetics likely play a role in the
development of LOAD. Many of
us are familiar with the unique
emotional weight an individual
and their family must shoulder
upon a diagnosis of AD. However,
few of us understand how years of
research has connected this disease
to bacterial and viral infections.
There is a tendency to as-

Figure 1 Neurofibrillary tangles (NFTs)
and Aβ plaques affect intracellular space
(within the cell, or neuron) and extracellular space (between cells in the brain).5
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Figure 2 A depiction of cold sores caused by HSV1 [15].

sume that each disease is special
– that each disease is diagnosed by
specific characteristics, leaving us
with a false sense of closure when
we can finally name our pain. This
is rarely the case. Dr. Alzheimer
said himself “how difficult it is
to define diseases with respect to
their clinical features”.12 For decades scientists have recognized
NFTs and Aβ plaques as characteristic of some chronic viral and bacterial infections. Certain pathogens can remain dormant in the
central nervous system for years,
and often a lifetime. These pathogens include herpes simplex virus
type 1 (HSV1), C. pneumoniae
(pneumonia), Borrelia burgdorferi
(Lyme disease), and other spirochetes (spirally shaped bacteria).6
Herpes and Alzheimer’s
The Center for Disease Control estimates that about 90% of
American adults are exposed to
the herpes simplex 1 virus (HSV1)
by the age of 60. This virus most
commonly manifests as cold sores
(Figure 2). The second form of the
herpes virus is the herpes simplex
2 virus (HSV2), which gets its rep22

utation from self-help books like
“how to live with herpes,” appearing in the form of genital sores.
About 1 in 6 people are estimated
to have genital herpes, according
to the CDC.13 Hearing the word
“herpes” makes many people run
for the hills. However, the reality
is that many of us have been exposed to herpes and it now quietly
resides in our CNS.2 HSV infection often lasts a lifetime and can
reactivate, producing cold sores.
Another more extreme form of
HSV1 is herpes encephalitis,
which is when the virus inhabits
the brain and induces dementia
with clinical features similar to
AD. Because of these similarities,
researchers have been hypothesizing a potential connection between
infections and AD for years.3
Researchers found that
AD-infected patients had less degeneration in brain regions containing more amounts of HSV1.14
This suggests that the presence of
the virus evoked some physiological response that was ultimately
protective. In contrast, Aβ was
found to prevent and reduce the
amount of HSV1 DNA replication. This would suggest that

more Aβ plaques reduces the viral infection, yet also spurs on the
neurodegenerative process as the
plaques accumulate.16 These results may mean that the presence
of HSV1 beneficially produces Aβ
and leads to greater preservation
of the brain. Seemingly contradictory results like these have left
scientists with inconclusive data.
Epidemiological studies advance
this discussion, further explaining the link between infection
and AD. In a study following 360
patients over 6 years researchers
found that those who were previously exposed to herpes were twice
as likely to develop AD compared
to those with no prior infection.17
Similarly, scientists followed an elderly population for 14 years, examining cognitive function every
few years. Baseline blood samples
showed who had been infected
with HSV prior to the 14-year investigation. They found that HSV
infection and the development of
AD were correlated, hinting that
early exposure to HSV may lead to
AD; however, it is also important
to remember the old saying that
correlation does not necessarily
equal causation.18 Though a causative relationship should be taken
with a grain of salt, another group
of researchers discovered that
HSV DNA is co-localized with
Aβ plaques in AD-infected brains,
further strengthening the association between infections and AD.19
Additionally, HSV1 and
AD have been linked genetically.
Mice with an ApoE genetic mutation had 13.7 times more HSV1
viral DNA present in their cells
compared to mice without a mu-
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tation.20 This genetic mutation,
as discussed before, is a risk factor
for AD. Thus, these data create an
interesting story illustrating how a
risk factor for developing AD could
also dictate the amount of virus
present in an individual. Despite
the interesting story being told by
years of research, no one has explored the clinical implications of
HSV and AD concurrency; could
anti-viral HSV treatment cure AD?
Pneumonia and Alzheimer’s
Pneumonia is a lung infection that
is currently the 6th leading cause
of death in America. While not
as common as herpes, community-acquired pneumonia (CAP),
or pneumonia acquired outside of
the hospital, still affects about 5.6
million Americans each year. C.
pneumoniae is a specific bacteria
that often causes CAP; however,
those infected with this bacteria
do not always develop symptoms
21
Multiple studies found that the
bacterium was present in most of
the AD-infected brains and in few
of the healthy brains, implicating
the bacteria as a risk factor for AD.
Researchers also found that the
bacterium was more prevalent in
areas of the brain most affected by
AD, such as the frontal, temporal,
and parietal cortex (Figure 3).3,23,24
Research linking C. pneumoni-

Figure 4 An image of a spirochete bacterium. Notice the spiral-shape, almost
like a corkscrew.26

ae to AD started in the 1990’s,
yet little has been done to develop this idea that the bacteria may
be causative. There is even research showing how the bacteria is able to spark cell death in
the brain. Despite these pivotal
findings, no research has been
done to determine if vaccines
can improve or prevent AD.

Figure 3 Research has shown that the
frontal (red), parietal (yellow), and temporal (purple) lobes are most susceptible
to AD and bacterial infection.

Spirochetes and
Alzheimer’s
The tick crawling on the floor
may seem harmless, but it
could be carrying bacteria called
Borrelia burgdorferi, most often referred to as Lyme disease.
Lyme disease infects approximately 300,000 Americans each
year, and this number continues
to grow.25 B. burgdorferi is a spirochete, meaning it is long and
spiral shaped (Figure 4). There are
many types of spirochetes – a form
of sexually transmitted disease that
causes dementia, one of which is
responsible for neurosyphilis.13
This bacterial-induced dementia
has similar pathological characteristics of AD, including a build-up
of spirochetes that are indistinguishable from AD plaques.6 Spirochetes have been detected more
frequently in AD-infected brains
than in healthy brains. The bacteria were also found in the same
areas as Aβ plaques in AD-infected brains, similar to findings
previously observed with HSV1
and C. pneumoniae.27 It seems
obvious that something is happening between AD and infections.
In addition, the number of
spirochetes in the brain increases

as the severity of dementia increases in individuals with an atrophic
form of general peresis – a disease
that leads to muscular weakness
from nerve damage. This was first
discovered in the 1920’s.3 The connection between the pathology of
infection-induced dementia and
AD pathology is apparent. It is
peculiar how such convincing data
and trends have been discussed
for decades without any progress
towards improving AD treatment.
Individuals with a higher infectious
burden have an increased risk of
cognitive decline. Elderly patients
exposed to multiple viruses were
2.5 times more likely to develop
cognitive impairments.28 A number of other epidemiological studies found that patients at risk of developing AD or with a confirmed
AD diagnosis were likely to have
been exposed to an infection at
some point in their life.14,18,25
AD is defined by standards set in the 1900’s and confirmation of diagnosis is still performed in the autopsy room. After
years of research, it seems crude
to diagnose AD based on clinical
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Figure 5 A beautiful yet daunting microscopic image of a virus.

features so similar to those present in infections. How can this
diagnosis be so confidently made
when symptoms across AD, herpes encephalitis, and neurosyphilis
are so similar? These diseases may
typically affect different populations, but that does not excuse
the potential confound during
diagnosis. A key piece to the puzzle connecting pathogens to AD
is the innate immune system.
The Innate Immune System
Living in a world full of viruses and bacteria, the human body
comes well equipped. Our bodies
are able to endure such trauma,
including microscopic trauma
that may go unnoticed. How do
our bodies endure? The innate
immune system protects both the
body and brain through activation
of various cells and proteins that
fight foreign pathogens. Scientists
are increasingly confident that Aβ
is part of the innate immune system. As mentioned previously, Aβ
prevention of HSV1 DNA replication suggests a protective role of
the protein.16 Shockingly, Aβ has
also been found to reduce bacterial growth and protect against
microbial infection.30,31 It turns
out that the protein that goes haywire in AD actually protects our
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brain from harmful pathogens.
If you recall, ApoE genetic mutations are risk factors for
AD. Interestingly, ApoE genetic
mutations similarly play a protective role. Children with heavier
burdens of diarrhea actually performed better on cognitive tests
if they had a genetic mutation of
ApoE.32 Thus, this risk factor for
AD can be protective depending
on the circumstances. While this
may seem surprising, the idea
that characteristics of a disease
may be protective is not novel.
For example, sickle cell anemia
protects people from malaria in
some parts of the world.33 In order to find a cure for AD, and the
“holy grail of science” we need to
consider all possibilities, including the idea that AD treatment
might include anti-viral treatment or vaccination (Figure 6).8
Over the range of pathogens aforementioned, one thing
remains a common denominator. After decades of research and
numerous published reviews of
research describing the poten-

Figure 6 “The grail may be closer than
meets the eye” by Mary Sawyer. Adapted
from “Cartoon scientist with magnifying
glass” by Boris Klissourski.

Figure 7 Image of the Swedish flag
overlaying the country of Sweden.35

tial role of infections in AD, few
strides have been made to clinically study these momentous scientific findings. Finally, the first study
will be conducted in Sweden using
herpes anti-viral treatment for AD
patients (Figure 7). Prior research
suggests that if Aβ accumulates
around the virus, then killing
the virus will also reduce the Aβ
plaques and potentially ameliorate
symptoms of AD.34 They started
enrolling participants in December 2016, but have not released
outcomes of their clinical trials. If
there is such a link between AD
and infections, why are we now
just trying anti-viral treatment to
cure AD? Why has it taken so long
to test this hypothesis given the
decades of research? Potentially,
it is the stigmatization of sexually transmitted infections that has
prevented a full scope of research.
Maybe we have become blind to
solutions that have stared us in the
face for years. With vaccinations
for C. pneumoniae and anti-viral treatment for HSV1, it seems
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to be an obvious next step to test
whether these could slow the progression of AD in people. In fact,
research published in 2011 even
showed how antiviral treatments
reduced the amount of Aβ plaques
and NFTs in cells.36 It seems that
Sweden is leading the rest of the
scientific community in this race
to find a cure. Hopefully, their
clinical trials will pique the curiosity of other scientists around the
world and advance the field of AD
research. As a captivated audience,
we must remember the role we
play – clinical trials are nonexistent
without willful participants. Not
only that, but a public engaged
with the sciences will encourage
funding for the most sought after research. While AD research
is currently caught in the public
eye, a link between the disease and
common infections is not exactly
what people want to hear. That being said, science is not about sharing pleasantries, it is about finding
the truth however hard that may
be to digest. For now I propose
a call to all scientists: it is time
to follow Sweden’s lead and take
this work to the clinical realm.
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